<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39375581</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1129-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>The journal of headache and pain</Title><ISOAbbreviation>J Headache Pain</ISOAbbreviation></Journal><ArticleTitle>Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.</ArticleTitle><Pagination><StartPage>169</StartPage><MedlinePgn>169</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">169</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s10194-024-01858-4</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aimed to comprehensively assess the safety of rimegepant administration in real-world clinical settings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from the Food and Drug Administration Adverse Event Reporting System (FAERS) spanning the second quarter of 2020 through the first quarter of 2023 were retrospectively analyzed in this pharmacovigilance investigation. This study focuses on employing subgroup analysis to monitor rimegepant drug safety. Descriptive analysis was employed to examine clinical characteristics and concomitant medication of adverse event reports associated with rimegepant, including report season, reporter country, sex, age, weight, dose, and frequency, onset time, et al. Correlation analysis, including techniques such as violin plots, was utilized to explore relationships between clinical characteristics in greater detail. Additionally, four disproportionality analysis methods were applied to assess adverse event signals associated with rimegepant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 5,416,969 adverse event reports extracted from the FAERS database, 10, 194 adverse events were identified as the "primary suspect" (PS) drug attributed to rimegepant. Rimegepant-associated adverse events involved 27 System Organ Classes (SOCs), and the significant SOC meeting all four detection criteria was "general disorders and administration site conditions" (SOC: 10018065). Additionally, new significant adverse events were discovered, including "vomiting projectile" (PT: 10047708), "eructation" (PT: 10015137), "motion sickness" (PT: 10027990), "feeling drunk" (PT: 10016330), "reaction to food additive" (PT: 10037977), etc. Descriptive analysis indicated that the majority of reporters were consumers (88.1%), with most reports involving female patients. Significant differences were observed between female and male patients across age categories, and the concomitant use of rimegepant with other medications was complex.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study has preliminarily identified potential new adverse events associated with rimegepant, such as those involving the gastrointestinal system, nervous system, and immune system, which warrant further research to determine their exact mechanisms and risk factors. Additionally, significant differences in rimegepant-related adverse events were observed across different age groups and sexes, and the complexity of concomitant medication use should be given special attention in clinical practice.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jia-Ling</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing-Ying</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Shi-Yan</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China. jiangcheng0818@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Guo-Qing</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China. gq_zheng@sohu.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Headache Pain</MedlineTA><NlmUniqueID>100940562</NlmUniqueID><ISSNLinking>1129-2369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse events</Keyword><Keyword MajorTopicYN="N">Data mining</Keyword><Keyword MajorTopicYN="N">FAERS</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword><Keyword MajorTopicYN="N">Rimegepant</Keyword><Keyword MajorTopicYN="N">Sex disparities</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375581</ArticleId><ArticleId IdType="doi">10.1186/s10194-024-01858-4</ArticleId><ArticleId IdType="pii">10.1186/s10194-024-01858-4</ArticleId><ArticleId IdType="pmc">PMC11460227</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders 3rd edn. Cephalalgia 38(1): 1–211. 10.1177/0333102417738202</Citation><ArticleIdList><ArticleId IdType="pubmed">29368949</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD (2016) Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Global Health Metrics 390(10100): 1211–1259. 10.1016/S0140-6736(17)32154-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5605509</ArticleId><ArticleId IdType="pubmed">28919117</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissardo JP, Caprara ALF (2022) Gepants for acute and preventive migraine treatment: a narrative review. Brain Sciences 12(12): 1612. 10.3390/brainsci12121612</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9775271</ArticleId><ArticleId IdType="pubmed">36552072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CC, Schwedt TJ (2020) Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine—The monoclonal antibodies and gepants. Progress in Brain Research 143–170. 10.1016/bs.pbr.2020.06.019</Citation><ArticleIdList><ArticleId IdType="pubmed">33008505</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter U, Goadsby PJ, et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161). 10.1016/S0140-6736(18)32534-0</Citation><ArticleIdList><ArticleId IdType="pubmed">30360965</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair HA (2023) Rimegepant: a review in the acute treatment and preventive treatment of migraine. CNS Drugs 37(3):255–265. 10.1007/s40263-023-00988-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10299922</ArticleId><ArticleId IdType="pubmed">36739335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton R B, Croop R, Stock EG et al (2019) Rimegepant, an oral calcitonin gene–related peptide receptor antagonist, for migraine. New England Journal of Medicine 381(2):142–149. 10.1056/NEJMoa1811090</Citation><ArticleIdList><ArticleId IdType="pubmed">31291516</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Sun W (2019) Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine. Front Pharmacol 10:795. 10.3389/fphar.2019.00795</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640487</ArticleId><ArticleId IdType="pubmed">31354502</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Gu S, Shen Z et al (2023) Evaluating ubrogepant-related adverse events using the FDA adverse event reporting system. Expert Opinion on Drug Safety 1–7. 10.1080/14740338.2023.2251390</Citation><ArticleIdList><ArticleId IdType="pubmed">37608560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigal M, Rapoport A et al (2007) Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 47(4). 10.1111/j.1526-4610.2007.00752</Citation><ArticleIdList><ArticleId IdType="pubmed">17445096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gérard AO, Merino D, Van Obberghen EK et al (2022) Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. The Journal of Headache and Pain 23(1):53. 10.1186/s10194-022-01424-w</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9066820</ArticleId><ArticleId IdType="pubmed">35505285</ArticleId></ArticleIdList></Reference><Reference><Citation>Szkutnik-Fiedler D (2020) Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs-lasmiditan, gepants, and Calcitonin-Gene-Related Peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics 12(12): 1180. 10.3390/pharmaceutics12121180</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7761673</ArticleId><ArticleId IdType="pubmed">33287305</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger AA, Winnick A et al (2022) Rimegepant for the treatment of migraine. Health Psychology Research 10(5). 10.52965/001c.38534</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9560892</ArticleId><ArticleId IdType="pubmed">36262478</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajti J, Szok D et al (2023) The pharmacotherapeutic management of episodic and chronic migraine with gepants. Expert Opin Pharmacother 24(8):947–958. 10.1080/14656566.2023.2201375</Citation><ArticleIdList><ArticleId IdType="pubmed">37038933</ArticleId></ArticleIdList></Reference><Reference><Citation>Battini V, Carnovale C et al (2023) Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the food and drug administration adverse event reporting System. Expert Opinion on Drug Safety 1–8. 10.1080/14740338.2023.2223958</Citation><ArticleIdList><ArticleId IdType="pubmed">37293948</ArticleId></ArticleIdList></Reference><Reference><Citation>Porreca F, Navratilova E et al (2024) Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia: Int J Headache 44(3). 10.1177/03331024241238153</Citation><ArticleIdList><ArticleId IdType="pubmed">38477313</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C, Qian J et al (2024) Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety. Pharmacology research &amp; perspectives 12(1). 10.1002/prp2.1161</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10765455</ArticleId><ArticleId IdType="pubmed">38174838</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y, Li J et al (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib. Scientific reports 14(1). 10.1038/s41598-024-62356-w</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11102445</ArticleId><ArticleId IdType="pubmed">38762672</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C, Zheng X et al (2024) A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime. Therapeutic Adv Drug Saf 15:20420986241258049. 10.1177/20420986241258049</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11177735</ArticleId><ArticleId IdType="pubmed">38881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen MT, Li JC et al (2024) Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS). Front Pharmacol 15:1391356. 10.3389/fphar.2024.1391356</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11335658</ArticleId><ArticleId IdType="pubmed">39170708</ArticleId></ArticleIdList></Reference><Reference><Citation>Altebainawi AF, Alfaraj LA et al (2023) Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. Therapeutic Adv drug Saf 14. 10.1177/20420986231154075</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9974623</ArticleId><ArticleId IdType="pubmed">36875514</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Xu YL et al (2020) Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS data in the past 15 Years. Oncology Research and Treatment 43(3). 10.1159/000505376</Citation><ArticleIdList><ArticleId IdType="pubmed">31945768</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M, Shu Y et al (2022) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep 12(1). 10.1038/s41598-022-23726-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9709073</ArticleId><ArticleId IdType="pubmed">36446798</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Shu Y et al (2022) A real-world pharmacovigilance study of FDA adverse event reporting System (FAERS) events for osimertinib. Sci Rep 12(1):19555. 10.1038/s41598-022-23834-1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9664039</ArticleId><ArticleId IdType="pubmed">36380085</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Dong C et al (2022) Post-marketing safety of vemurafenib: a real-world pharmacovigilance study of the FDA adverse event reporting System. J Pharm Pharm Sci 25:377–390. 10.18433/jpps33020</Citation><ArticleIdList><ArticleId IdType="pubmed">36608646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Zfeng, Kong X et al (2024) Global, regional, and national burden and trends of migraine among youths and young adults aged 15–39 years from 1990 to 2021: findings from the global burden of disease study 2021. J Headache Pain 25(1):131. 10.1186/s10194-024-01832-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11318134</ArticleId><ArticleId IdType="pubmed">39134934</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman G, Croop R et al (2020) Safety of Rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for Migraine. Headache 60(8):1734–1742. 10.1111/head.13930</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496574</ArticleId><ArticleId IdType="pubmed">32799325</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, San X et al (2024) Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database. Sci Rep 14(1):7489. 10.1038/s41598-024-57909-y</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10980721</ArticleId><ArticleId IdType="pubmed">38553504</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis S, Carlson AK et al (2023) Impacts of climate change and air pollution on neurologic health, Disease, and practice: a scoping review. Neurology 100(10):474–483. 10.1212/WNL.0000000000201630</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9990849</ArticleId><ArticleId IdType="pubmed">36384657</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Siddique R et al (2024) Towards improving the prognosis of stroke through targeting the circadian clock system. Int J Biol Sci 20(2):403–413. 10.7150/ijbs.88370</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10758097</ArticleId><ArticleId IdType="pubmed">38169640</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugge NS, Vetvik KG et al (2024) Cumulative exposure to estrogen may increase the risk of migraine in women. Cephalalgia: Int J Headache 44(1). 10.1177/03331024231225972</Citation><ArticleIdList><ArticleId IdType="pubmed">38215242</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Li H et al (2024) A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database. Front Pharmacol 15. 10.3389/fphar.2024.1368244</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11169801</ArticleId><ArticleId IdType="pubmed">38873427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Ding L et al (2023) Updated insights on dementia-related risk of sacubitril/valsartan: a real-world pharmacovigilance analysis. CNS Neurosci Ther 29(9). 10.1111/cns.14195</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10401082</ArticleId><ArticleId IdType="pubmed">36971193</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott LJ (2020) Rimegepant First Approval. Drugs 80(7):741–746. 10.1007/s40265-020-01301-3</Citation><ArticleIdList><ArticleId IdType="pubmed">32270407</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong G, Kjærgaard NA et al (2023) Ubrogepant and Rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies. Exp Opin Drug Saf 22(1):59–70. 10.1080/14740338.2023.2177270</Citation><ArticleIdList><ArticleId IdType="pubmed">36737057</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang D, Sessa M (2022) Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. Exp Opin Drug Saf 21(9):1205–1210. 10.1080/14740338.2022.2049231</Citation><ArticleIdList><ArticleId IdType="pubmed">35236231</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinesh S (2023) Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine. Inflammopharmacology. 10.1007/s10787-023-01276-z</Citation><ArticleIdList><ArticleId IdType="pubmed">37421480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ak C, Yy L (2018) Neurophysiological symptoms and aspartame: What is the connection? Nutritional neuroscience 21(5). 10.1080/1028415X.2017.1288340</Citation><ArticleIdList><ArticleId IdType="pubmed">28198207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rainsford KD (2013) Ibuprofen: from invention to an OTC therapeutic mainstay. Int J Clin Pract Suppl (178):9–20. 10.1111/ijcp.12055</Citation><ArticleIdList><ArticleId IdType="pubmed">23163543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjarnason I (2013) Gastrointestinal safety of NSAIDs and over-the-counter analgesics. Int J Clin Pract Suppl (178):37–42. 10.1111/ijcp.12048</Citation><ArticleIdList><ArticleId IdType="pubmed">23163547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>